TAVNEOS®, as adjunctive therapy to standard immunosuppressive treatment based on rituximab or cyclophosphamide with GCs, is indicated for the treatment of adult patients with severe, active ANCA-associated vasculitis (GPA and MPA)3
TAVNEOS® must be initiated and monitored by healthcare professionals experienced in the diagnosis and treatment of ANCA-associated vasculitis (GPA and MPA)3
achieved non-inferior clinical remission at Week 26 and superior sustained clinical remission at Week 52 vs a
GC-based regimen1†
resulted in a lower absolute risk of relapse vs a GC-based regimen over 52 weeks1
EFFICACY
demonstrated sustained improvement in renal function over 1 year vs a GC-based regimen1
RENAL FUNCTION
allowed physicians to reduce GC use with a signicant reduction in GC toxicity vs a GC-based regimen1,4
GC TOXICITY
demonstrated signicant improvements in physical and health-related domains of QoL vs a GC-based regimen1
QUALITY OF LIFE
includes TAVNEOS® taken as a fixed oral dose3
DOSING
TAVNEOS® demonstrated a favourable safety profile1
SAFETY
TAVNEOS® is the first targeted treatment2 for AAV already recognised in the EULAR 2022 recommendations6
INNOVATIVE MOAIntroducing TAVNEOS®: a first-in-class targeted treatment for GPA/MPA2
Discover how to use TAVNEOS®
*In the ADVOCATE trial, significantly lower GC toxicity was observed in the TAVNEOS®-combined therapy compared to the GC-based therapy.1
†Clinical remission in the ADVOCATE study was defined as BVAS 0 and no GC use in previous 4 weeks.1
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; EQ-5D-5L, EuroQoL-5 dimension-5 level; EULAR, European Alliance of Associations for Rheumatology; GC, glucocorticoid; GPA, granulomatosis with polyangiitis; MOA, mechanism of action; MPA, microscopic polyangiitis; QoL, quality of life; ; VAS, Visual Analogue Scale.
1. Jayne D, et al. N Engl J Med 2021;384(7):599–609. 2. EMA. First-in-class medicine recommended for treatment of rare blood vessel inflammation. Nov. 2021. https://www.ema.europa.eu/en/news/first-class-medicine-recommended-treatment-rare-blood-vessel-inflammation. Last access: October 2023. 3. TAVNEOS® Fachinformation, www.swissmedicinfo.ch. 4. Stone J, et al. Semin Arthritis Rheum 2022;55:152010. 5. Strand V, et al. Lancet Rheumatol 2023;5:e451–60. 6. Hellmich B, et al. Ann Rheum Dis 2023;0:1–18.
This medicinal product is subject to additional monitoring. For further information, see professional information TAVNEOS® on www.swissmedicinfo.ch.
Scroll down
